Oxford Biomedica recebe permissão para patente nos E.U.A. do Prosavin®

26 Jun 2006 - (...) ProSavin is Oxford BioMedica's lead neurobiology candidate product for the treatment of Parkinson's disease. ProSavin uses a LentiVector® system to deliver the genes for three enzymes that are required for the synthesis of dopamine. The three genes are AADC (aromatic amino acid dopa decarboxylase), TH (tyrosine hydroxylase) and CH1 (GTP-cyclohydrolase 1). The product is administered locally to the striatum, where these genes are able to reprogramme transduced cells to manufacture and secrete dopamine. Gene expression is sustained over several months, a key requirement for the product to be clinically successful. This new endogenous source of the neurotransmitter replaces the patient's own lost source of dopamine. (segue...) Fonte: Medical News Today.
Veja o que já foi publicado sobre o tema, neste Blog, em 23/07/2004.